Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-world data reveals how a kidney drug impacts daily life and delays dialysis

NCT ID NCT02925221

Completed Knowledge-focused Sponsor: Otsuka Canada Pharmaceutical Inc. Source: ClinicalTrials.gov ↗

First seen Jan 09, 2026 · Last updated May 13, 2026 · Updated 18 times

Summary

This study followed 530 adults with autosomal dominant polycystic kidney disease (ADPKD) who were already taking tolvaptan (JINARC™) as part of their routine care. Researchers measured how the drug affected patients' quality of life, pain, and ability to work, as well as how long it delayed the need for dialysis or a kidney transplant. The goal was to understand the real-world benefits and risks of tolvaptan beyond what was seen in earlier clinical trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Study site

    Edmonton, Alberta, Canada

  • Study site

    London, Ontario, Canada

  • Study site

    Ottawa, Ontario, Canada

  • Study site

    Toronto, Ontario, Canada

  • Study site

    Montreal, Quebec, Canada

  • Study site

    Québec, Quebec, Canada

Conditions

Explore the condition pages connected to this study.

AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)